Synektik Sa · GPW:SNT
Synektik Sa — 9M FY2025 Earnings Presentation
19 slides from Synektik Sa's earnings presentation, August 2026
Slide 1: Financial results for 9M 2025
SYNEKTIK SA Financial results for 9M 2025 Investor presentation August 2026 Financial results for Q3 2025 | Investor presentation 1
Slide 2: Synektik at a glance
Synektik at a glance WIG, mWIG40, Indices WIGTECH, WIG-Poland PLN 733m REVENUE FROM SALES PLN 190m EBITDA FROM CONTINUING ISIN Number of shares PLSNKTK0001 8,529,129 Market capitalization(1) PLN 3.09 billion IN 9M FY 2025 OPERATIONS FOR 9M FY2025 Enterprise value(2) PLN 3.05 billion P/E(3) 17.3 EV/E
Slide 3: Key events October 2025 – August 2026
Key events October 2025 – August 2026 Sales of equipment and IT solutions – sales growth, international expansion PLN 692.5 million in revenue (excluding intra-group transactions) for 9M FY2025 (up 56%), including PLN 291.0 million in recurring revenue (up 28% year-on- year); PLN 197.1 million in
Slide 4: Financial results for 9M FY2025 (PLN million)
Financial results for 9M FY2025 (PLN million) Consolidated revenue 9M 56% increase in revenue from equipment sales, IT solutions and services 733.4 FY2025 (excluding intra-group transactions) +52% 9M 7% increase in revenue from the radiopharmaceuticals segment FY2024 482.1 (excluding intra-group
Slide 5: Financial results for Q3 FY2025 (PLN million)
Financial results for Q3 FY2025 (PLN million) Consolidated revenue Q3 100% increase in revenue from the sale of equipment, IT solutions and 292.3 FY2025 services (excluding intra-group transactions) +89% Q3 Revenue in the radiopharmaceuticals segment (excluding intra-group FY2024 154.2 transacti
Slide 6: The Group's adjusted EBITDA for the financial years 2022-2025
The Group’s adjusted* EBITDA for the financial years 2022-2025 Adjusted EBITDA* EBITDA growth drivers: (PLN million) 71.5 Growth in the Group’s recurring revenue 59.8 58.2 52.7 50.5 55.2 in both business segments, characterized 41.6 by attractive margins 29.8 30.4 31.7 31.7 33.8 24.9 24.9 Increa
Slide 7: Recurring sales in financial years 2022-2025
Recurring sales in financial years 2022-2025 Recurring revenue for the last 4 quarters Rapid growth in recurring sales (PLN million) Growth drivers: 41.2 39.2 Rapidly growing demand for consumable 37.5 parts and accessories for therapy equipment 35.8 sold by the Synektik Group 35.0 Revenues from s
Slide 8: Financial highlights
Financial highlights PLN 000s Q3 FY2025 Q3 FY2024 9M FY2025 9M FY2024 Revenue from sales 292,265 154,238 733,427 482,060 PLN 141.4 million in positive operating cash flow EBIT* 66,126 36,435 173,816 107,496 over the 9-month period of the current financial Operating margin* 23% 24% 24% 22% EBITDA*
Slide 9: Medical equipment and IT solutions
SYNEKTIK SA Medical equipment and IT solutions Financial results for Q3 2025 | Investor presentation 9
Slide 10: Medical equipment and IT solutions: Key information
Medical equipment and IT solutions Key information Synektik is a leading provider of medical devices and IT solutions used in radiology, oncology, cardiology and neurology Core areas of business: Sales of medical equipment from over a dozen leading manufacturers, used in radiology, therapy and nuc
Slide 11: Medical equipment and IT solutions: Financial results
Medical equipment and IT solutions Financial results (PLN million) Rapid growth in revenue and profits 692.5 Revenue doubled (year-on-year) in Q3 FY2025, to PLN 278.9 million 443.7 78% increase in segment EBITDA, to PLN 76.1 million 197.1 125.6 56% year-on-year revenue growth in 9M FY2025, to
Slide 12: Record-breaking contract awards, promising outlook
Medical equipment and IT solutions Record-breaking contract awards, promising outlook Sales of medical equipment, backlog and active offers (PLN million) 423.0 401.6 Backlog worth PLN 423.0 million in 9M FY2025; backlog worth PLN 112.0 million in Q3 Accumulation, in Q3 of this year, of contract
Slide 13: Commercialization of da Vinci systems
Medical equipment and IT solutions Commercialization of da Vinci systems da Vinci-assisted surgical procedures in Poland, the Czech Republic and Slovakia (number) 11000 122 10000 ▪ 6,900 da Vinci-assisted procedures in Q3 of the financial year 2025 in Poland (35% year-on-year increase) 9000 ▪ Over 4
Slide 14: da Vinci systems under the care of the Synektik Group
Medical equipment and IT solutions Gdynia Wejherowo Słupsk Da Vinci serviced by GK Synektik Gdańsk Grudziądz Olsztyn 142 100 Szczecin Białystok Bydgoszcz Włocławek Toruń Wieliszew Biała Podlaska Grodzisk da Vinci systems under da Vinci systems Gorzów Wlkp. Maz. the care of the Synektik Group in Pola
Slide 15: Radiopharmaceuticals
SYNEKTIK SA Radiopharmaceuticals Financial results for Q3 2025 | Investor presentation 15
Slide 16: Radiopharmaceuticals: Key information
Radiopharmaceuticals Key information Synektik is Poland’s largest manufacturer and supplier of radiopharmaceuticals 55+ Number of 3 Production facilities employees and R&D Center used in PET/CT diagnostics Leader in the production of specialty radiopharmaceuticals Location of cyclotrons used to
Slide 17: Growth in sales of radiopharmaceuticals
Radiopharmaceuticals Growth in sales of radiopharmaceuticals Financial results (PLN million) 40.9 38.3 PLN 13.4 million in revenue in Q3 FY2025, compared to PLN 14.8 million a year earlier Sales of basic tracers increased by PLN 0.1 million, to PLN 7.2 million 12.9 12.3 Sales of special tracer
Slide 18: Q&A session
SYNEKTIK SA Q&A session Financial results for Q3 2025 | Investor presentation 18
Slide 19: Thank you
PLEASE FEEL FREE TO CONTACT US Thank you Cezary Kozanecki President of the Management Board ckozanecki@synektik.com.pl Dariusz Korecki Vice President of the Management Board, CFO dkorecki@synektik.com.pl